Why Merck is more than a patent-cliff story
Merck is one of those large pharmaceutical companies that gets reduced to a single question: what happens when the biggest oncology franchise eventually faces patent pressure? That question matters, but it can also flatten the real investment debate. The better question is whether Merck is building enough additional earnings power around that franchise to make the transition manageable rather than destabilizing.
The current portfolio suggests it is trying to do exactly that. Merck still depends heavily on oncology, but the company is no longer relying on a single product category to carry the entire growth story. Animal Health remains a meaningful contributor, newer launches are gaining scale, and management keeps using business development to broaden the pipeline. That does not eliminate concentration risk, but it does change the shape of it.
What the latest results say about Merck’s portfolio mix
In the first quarter of 2026, Merck reported total worldwide sales of $16.286 billion, up 5% year over year, or 3% excluding foreign exchange. KEYTRUDA and KEYTRUDA QLEX generated $8.0 billion of sales, up 12%, which still shows how central oncology remains. But the quarter also highlighted that Merck is not standing still elsewhere. WINREVAIR sales reached $525 million, up 88%, and Animal Health sales were $1.8 billion, up 13%.
Those numbers matter because they show multiple growth vectors working at the same time. Merck also raised the midpoint of its full-year 2026 sales outlook, narrowing the range to $65.8 billion to $67.0 billion, and lifted its non-GAAP EPS range to $5.04 to $5.16. Management explicitly said the outlook does not reflect the proposed Terns acquisition, so the guidance move came from the operating base rather than from a deal model.
The annual numbers tell a similar story. For full-year 2025, Merck reported worldwide sales of $65.0 billion. KEYTRUDA and KEYTRUDA QLEX contributed $31.7 billion, WINREVAIR added $1.4 billion, CAPVAXIVE added $759 million, and Animal Health produced $6.4 billion of sales, up 8%. Just as important, those gains came even as GARDASIL and GARDASIL 9 sales fell 39% in 2025. In other words, Merck already had one important pressure point in the portfolio and still produced growth.
Why animal health and new launches matter for durability
Animal Health is easy to overlook because it lacks the headline impact of oncology approvals, but that is exactly why it matters. It gives Merck a sizable, operating business outside human biopharma that can add cash flow and reduce dependence on any one therapeutic category. A $1.8 billion quarterly run rate and $6.4 billion in annual sales are too large to dismiss as a side business.
Newer launches matter for a different reason. WINREVAIR’s growth shows Merck can still scale fresh assets into meaningful revenue contributors, while CAPVAXIVE and other pipeline assets broaden the base from which the company can offset future exclusivity losses. Investors should not pretend those products replace KEYTRUDA overnight. They do not. But they do make Merck’s future less binary than the usual narrative suggests.
Merck is also using external pipeline building to keep that diversification process moving. The company said in Q1 that it had agreed to acquire Terns Pharmaceuticals to expand its hematology pipeline and reminded investors that recent business development had already augmented its broader portfolio. That willingness to buy or license science is not automatically a positive, but it does show management is acting as if time matters.
What investors should watch next
The main thing to watch is not whether KEYTRUDA remains dominant. It almost certainly will for now. The real test is whether everything around it keeps becoming more material. Investors should track Animal Health growth, the pace of WINREVAIR adoption, the contribution from newer launches such as CAPVAXIVE, and whether management can keep guiding the broader revenue base higher even when one product category faces pressure.
There is also an important quality-of-growth question. Q1 2026 included a large acquisition-related charge tied to Cidara, which pushed Merck to a GAAP loss and a non-GAAP loss for the quarter. That makes it even more important to separate operating sales momentum from deal accounting noise. So far, the sales side still looks solid.
Merck will eventually have to prove it can move from a company with one giant pillar to one with several sturdy ones. The portfolio today is not fully there yet. But Animal Health, oncology depth, and newer launch momentum suggest investors should analyze Merck as a diversification-in-progress story, not just a patent-cliff countdown.
Key Signals for Investors
- Q1 2026 worldwide sales rose 5% to $16.286 billion.
- KEYTRUDA and KEYTRUDA QLEX generated $8.0 billion in Q1 2026 sales, up 12%.
- WINREVAIR sales reached $525 million in Q1 2026, while Animal Health sales rose 13% to $1.8 billion.
- Full-year 2025 sales were $65.0 billion, including $31.7 billion from KEYTRUDA and KEYTRUDA QLEX and $6.4 billion from Animal Health.
- Merck raised the midpoint of its 2026 sales and non-GAAP EPS outlook after Q1.
Source link
#Merck #MRK #Keytruda #Story #Animal #Health #Launches #Scaling #Alphastreet
